Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Bestmade Natural Products Bio10
Generic Name
Calc Phos, Ferr Phos, Kali Mur
Active Ingredient
FerrosoferricCategory
Vitamin C [EPC]
Salt Form
Phosphate
Variants
2
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 6 [hp_X]/6[hp_X] | LIQUID | ORAL | 82969-9010 |
| 6 [hp_X]/6[hp_X] | TABLET, SOLUBLE | ORAL | 82969-3010 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Bestmade Natural Products Bio10, you must consult a qualified healthcare professional.
Detailed information about Bestmade Natural Products Bio10
Ferrosoferric is a complex mineral compound primarily utilized as a parenteral iron replacement and phosphate binder. It plays a critical role in managing iron deficiency anemia and hyperphosphatemia in patients with chronic kidney disease.
Dosage for Ferrosoferric is highly individualized based on the patient's serum iron levels, phosphate levels, and overall renal function.
Ferrosoferric use in pediatric patients must be strictly monitored by a specialist. Dosing is typically weight-based (e.g., 2-3 mg/kg of elemental iron equivalent). Safety and efficacy in children under the age of 12 for certain indications have not been fully established.
In patients with chronic kidney disease, Ferrosoferric is often used because of renal impairment. However, the dose must be carefully titrated based on serum phosphorus and calcium-phosphorus product levels. No specific adjustment is required for the iron replacement component, though monitoring for iron overload is essential.
Use with caution in patients with hepatic dysfunction, as the liver is a primary storage site for iron. Frequent monitoring of liver function tests (LFTs) and ferritin levels is recommended.
Clinical studies have not identified significant differences in responses between the elderly and younger patients. However, dose selection should be cautious, usually starting at the low end of the dosing range due to the higher frequency of decreased hepatic or cardiac function.
For optimal results, follow these guidelines:
If you miss a dose, take it as soon as you remember with your next meal. If it is almost time for your next scheduled dose, skip the missed dose. Do not double the dose to catch up.
Signs of iron overdose (toxicity) include severe vomiting, abdominal pain, bloody diarrhea, and lethargy. In severe cases, it can lead to metabolic acidosis and hepatic failure. If an overdose is suspected, contact a poison control center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Patients taking Ferrosoferric frequently report gastrointestinal symptoms. These are often dose-dependent and may include:
Before starting Ferrosoferric, ensure your healthcare provider has a full list of your medical history. This medication can significantly alter mineral balances in the blood, which may affect heart and nerve function.
No FDA black box warnings for Ferrosoferric. However, clinical guidelines emphasize the risk of iron toxicity in pediatric populations; accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6.
Ferrosoferric must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis by your physician include:
Ferrosoferric is classified as Pregnancy Category C. While iron is essential during pregnancy, there are limited controlled studies on the use of Ferrosoferric phosphate specifically. It should be used only if the potential benefit justifies the potential risk to the fetus. High-dose parenteral iron in the first trimester is generally avoided unless absolutely necessary.
Iron is naturally excreted in breast milk. While Ferrosoferric is unlikely to cause harm to a nursing infant, the effects of the phosphate-binding complex on milk composition are not fully understood. Consult your doctor to weigh the benefits of breastfeeding against the clinical need for the drug.
Safety and effectiveness in pediatric patients have been established primarily for iron deficiency. Its use as a phosphate binder in children is considered off-label in many jurisdictions and requires expert nephrological supervision to avoid interfering with bone growth.
Ferrosoferric acts as a Phosphate Chelator. In the acidic environment of the stomach, the compound dissociates, allowing the iron moiety to bind with dietary phosphate ions to form insoluble iron phosphate. This prevents the absorption of phosphate across the intestinal epithelium. Additionally, its role as a Parenteral Iron Replacement involves the delivery of elemental iron to the reticuloendothelial system, where it is processed and released to transferrin for erythropoiesis (red blood cell production).
The onset of phosphate-binding action is immediate upon contact with food in the stomach. However, the reduction in serum phosphorus levels typically takes 1 to 2 weeks of consistent therapy. The hematologic response to the iron component (increased reticulocyte count) is usually observed within 7 to 10 days, with hemoglobin levels rising over 2 to 4 weeks.
| Parameter | Value |
Common questions about Bestmade Natural Products Bio10
Ferrosoferric is primarily used for two major clinical purposes: managing high phosphate levels (hyperphosphatemia) in patients with chronic kidney disease and treating iron deficiency anemia. As a phosphate binder, it works in the gut to prevent the absorption of phosphorus from food. As an iron replacement, it provides the necessary mineral for the body to produce healthy red blood cells. Your doctor may also use it for its acidifying properties in specific metabolic conditions. It is a versatile mineral compound that requires careful medical supervision to maintain proper blood chemistry balances.
The most frequently reported side effects of Ferrosoferric are gastrointestinal in nature, including nausea, diarrhea, and constipation. A very common but harmless side effect is the appearance of dark or black-colored stools, which is caused by unabsorbed iron passing through the digestive tract. Some patients may also experience abdominal bloating or a metallic taste in the mouth. These symptoms are often dose-dependent and may improve as your body adjusts to the medication. If side effects become severe or persistent, you should contact your healthcare provider for a dosage adjustment.
It is generally advised to limit or avoid alcohol consumption while taking Ferrosoferric. Alcohol can increase the risk of stomach irritation and may interfere with the absorption of the medication. Furthermore, chronic heavy drinking can lead to increased iron storage in the liver, which, when combined with iron-containing medications, increases the risk of iron toxicity. Alcohol can also complicate the management of chronic kidney disease, the condition for which Ferrosoferric is often prescribed. Always discuss your alcohol intake with your doctor to ensure it does not interfere with your treatment plan.
Ferrosoferric is generally used during pregnancy only when the potential benefits outweigh the risks, as it is classified as Pregnancy Category C. While iron is a necessary nutrient for fetal development, the specific effects of the ferrosoferric phosphate complex have not been extensively studied in pregnant women. High-dose iron can sometimes cause oxidative stress, and its impact on phosphate balance must be monitored. If you are pregnant or planning to become pregnant, your doctor will likely monitor your iron and mineral levels closely. Never start or stop this medication during pregnancy without direct medical advice.
The time it takes for Ferrosoferric to work depends on the condition being treated. For phosphate binding, the medication begins working immediately in the gut, but it may take 1 to 2 weeks of consistent use before your blood tests show a significant decrease in phosphorus levels. For iron deficiency anemia, you may start to feel an increase in energy within 2 weeks as your reticulocyte count rises. However, it typically takes 4 to 8 weeks of therapy to see a significant improvement in hemoglobin levels. Regular blood monitoring is necessary to track your progress and adjust the dose.
You should not stop taking Ferrosoferric suddenly without consulting your healthcare provider. If you are taking it to control phosphate levels in kidney disease, stopping the drug abruptly can cause your phosphorus levels to rise rapidly. This increase can lead to serious complications, including the calcification of blood vessels and heart tissues. If you are experiencing side effects that make you want to stop the medication, your doctor can often suggest ways to manage them or switch you to an alternative binder. Always follow the prescribed tapering or discontinuation schedule provided by your medical team.
If you miss a dose of Ferrosoferric, take it as soon as you remember, provided it is with a meal or snack. If it is almost time for your next scheduled dose, skip the missed dose entirely and resume your regular schedule. Do not take two doses at once to make up for a missed one, as this can increase the risk of stomach upset and mineral imbalances. Since the phosphate-binding action requires the presence of food, taking a dose without a meal is generally less effective. Keeping a consistent schedule with your meals is the best way to ensure the medication works correctly.
Weight gain is not a recognized or common side effect of Ferrosoferric. The medication works locally in the gut or enters the iron storage cycle and does not typically affect metabolic rate or appetite in a way that leads to weight gain. If you notice rapid weight gain or swelling (edema) while taking this medication, it may be related to your underlying kidney or heart condition rather than the drug itself. Such symptoms should be reported to your doctor immediately, as they may indicate fluid retention. Maintaining a healthy diet and monitoring your fluid intake is important for patients with conditions requiring Ferrosoferric.
Ferrosoferric can interact with several other medications, so caution is required. It is known to bind to certain antibiotics, thyroid medications, and osteoporosis drugs, which can prevent them from being absorbed properly. To avoid this, you should generally take other medications at least 2 hours before or 4 hours after your Ferrosoferric dose. Always provide your doctor or pharmacist with a complete list of all the supplements and medicines you are taking. They can help you create a dosing schedule that prevents these interactions and ensures all your treatments remain effective.
Ferrosoferric may be available in generic forms, though it is often found as a component of various brand-name iron supplements and phosphate binders. The availability of a generic version can depend on your country and the specific formulation (oral vs. injectable). Generic versions are required to meet the same FDA standards for safety and effectiveness as the brand-name products. Using a generic version can often be a more cost-effective option for long-term treatment. Ask your pharmacist or healthcare provider if a generic equivalent is available and appropriate for your specific medical needs.
Other drugs with the same active ingredient (Ferrosoferric)
> Warning: Stop taking Ferrosoferric and call your doctor immediately if you experience any of these:
Prolonged use of Ferrosoferric, particularly in high doses, can lead to chronic iron overload, which may damage the liver, heart, and pancreas. Regular monitoring of serum ferritin and transferrin saturation (TSAT) is required to prevent these complications. Additionally, long-term phosphate binding can sometimes lead to imbalances in other minerals, such as calcium and magnesium.
No FDA black box warnings are currently issued for Ferrosoferric. However, healthcare providers are cautioned regarding the risk of hypersensitivity reactions with parenteral iron products, which can be fatal. Ensure administration occurs in a facility equipped to handle emergency resuscitation.
Report any unusual symptoms to your healthcare provider.
Your doctor will require regular blood tests to ensure the medication is working safely:
Ferrosoferric generally does not interfere with the ability to drive or operate machinery. However, if you experience dizziness or low blood pressure after an injection, wait until these symptoms resolve before driving.
Alcohol can increase the risk of gastric irritation when taking oral Ferrosoferric. Chronic alcohol consumption can also lead to increased iron absorption, potentially raising the risk of iron overload.
Do not stop taking Ferrosoferric suddenly, especially if being used for phosphate binding in CKD, as this can lead to a rapid rise in phosphate levels, increasing the risk of cardiovascular calcification. Tapering is generally not required, but medical supervision is essential.
> Important: Discuss all your medical conditions with your healthcare provider before starting Ferrosoferric.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Patients who have reacted poorly to other iron salts (such as Ferrous Sulfate) or other phosphate binders (such as Lanthanum Carbonate) should be monitored closely, although cross-reactivity is not always guaranteed due to the unique chemical structure of Ferrosoferric.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ferrosoferric.
Elderly patients are more likely to experience constipation and gastrointestinal side effects. Lower starting doses and gradual titration are recommended to ensure tolerability. Monitor for potential interactions with other medications commonly taken by this age group (polypharmacy).
In patients with GFR < 30 mL/min, Ferrosoferric is a primary tool for managing hyperphosphatemia. However, these patients are at higher risk for mineral bone disease, requiring frequent monitoring of Parathyroid Hormone (PTH) levels.
No specific dose adjustment is provided for hepatic impairment, but caution is advised. In patients with Child-Pugh Class C cirrhosis, the risk of iron-induced oxidative stress on hepatocytes must be considered.
> Important: Special populations require individualized medical assessment.
| Bioavailability | <1% (as binder); 100% (IV iron) |
| Protein Binding | 90% + (to Transferrin) |
| Half-life | 6 to 30 hours (systemic iron) |
| Tmax | 2 to 4 hours (oral iron component) |
| Metabolism | Non-enzymatic; physiological recycling |
| Excretion | Fecal (unbound); Minimal Renal |
Ferrosoferric is classified as a Phosphate Binder and a Parenteral Iron Replacement. It is related to other iron-based binders such as sucroferric oxyhydroxide and ferric citrate.